Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries
Shots:
- Incyte will lead the development- manufacture- and supply of both products. ST will be responsible for the regulatory- distribution- and local marketing related activities in Australia- New Zealand & Singapore
- Tafasitamab + lenalidomide is approved in the US & EU to treat adult patients with r/r DLBCL who are not eligible for ASCT
- Pemigatinib is approved in the US- EU & Japan to treat LA or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that has progressed after one prior line of systemic therapy. In Jan'20- Incyte has entered into a collaboration and license agreement with MorphoSys to develop and commercialize tafasitamab globally
| Ref: PRNewswire | Image: ECIJA
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com